Oncolytics Biotech Inc.
ONCY
$0.80
-$0.01-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.00M | 18.61M | 16.11M | 13.08M | 10.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.07M | 33.35M | 29.09M | 26.81M | 24.02M |
| Operating Income | -38.07M | -33.35M | -29.09M | -26.81M | -24.02M |
| Income Before Tax | -37.90M | -33.78M | -29.25M | -26.87M | -23.22M |
| Income Tax Expenses | 118.80K | 78.80K | 78.80K | -101.40K | 90.40K |
| Earnings from Continuing Operations | -38.02 | -33.86 | -29.33 | -26.77 | -23.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.02M | -33.86M | -29.33M | -26.77M | -23.31M |
| EBIT | -38.07M | -33.35M | -29.09M | -26.81M | -24.02M |
| EBITDA | -38.01M | -33.28M | -29.02M | -26.74M | -23.94M |
| EPS Basic | -0.35 | -0.33 | -0.30 | -0.30 | -0.29 |
| Normalized Basic EPS | -0.22 | -0.20 | -0.19 | -0.19 | -0.18 |
| EPS Diluted | -0.35 | -0.33 | -0.30 | -0.30 | -0.29 |
| Normalized Diluted EPS | -0.22 | -0.20 | -0.19 | -0.19 | -0.18 |
| Average Basic Shares Outstanding | 439.65M | 410.91M | 383.25M | 354.52M | 330.22M |
| Average Diluted Shares Outstanding | 439.65M | 410.91M | 383.25M | 354.52M | 330.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |